Anti-infective Agents : Quinolones
ICRAV2 “Cravit IV Sol’n injection” 5 mg/ml; 50 ml/bot
OCRAV2 “Cravit FC tablet” 500 mg/tab
OLEFL1 “Leflodal FC tablet” 500 mg/tab
IBACF1 “Bacflocin IV Sol’n injection” 5 mg/ml; 50 ml/bot
適應症：
ICRAV2, IBACF1：治療成人因對 LEVOFLOXACIN有感受性的致病菌所引起之下列感染社區性肺炎、複雜性尿道感染(包括:腎盂腎炎)，皮膚和軟組織感染。慢性細菌性前列腺炎。
OCRAV2, OLEFL1：治療成人因對levofloxacin有感受性的致病菌所引起之下列感染：急性鼻竇炎、慢性支氣管炎的急性惡化、社區性肺炎、複雜性泌尿道感染（包括：腎盂腎炎）、皮膚和軟組織感染。
Usual dose: PO/IV
Susceptible infection: 500-750 qd.
UTI: 250 mg qd.
Precaution:
IV, infuse over at least 60 min (250 mg and 500 mg) or 90 min (750 mg).
Oral tablets, may take with or without food, do not give within 2 h of antacids, sucralfate, iron.
Dose adjustment:
Renal failure:
CrCl 20-49 ml/min, 750 mg initially then 750 mg q48h; CrCl 10-19 ml/min, 750 mg initially then 500 mg q48h; hemodialysis/CAPD, 750 mg initially then 500 mg q48h.
Inhalational anthrax: CrCl 20-49 ml/min, 500 mg initially then 250 mg q24h; CrCl 10-19 ml/min, 500 mg initially then 250 mg q48h; hemodialysis/CAPD, 500 mg initially then 250 mg q48h.
UTI: CrCl 10-19 ml/min, 250 mg initially then 250 mg q48h.
Adverse effect:
Common: injection site reaction, diarrhea, nausea, headache.
Serious: torsades de pointes, hyperglycemia, hypoglycemia, usually in diabetic p’ts, hypersensitivity reaction, rupture of tendon.
健保使用規範：限用於成人（18歲以上）之慢性支氣管炎的急性惡化、社區性肺炎、複雜性泌尿道感染。若使用於結核病不予給付。